Inhibition of inflammasome activation and caspase-1-dependent IL-1β production have already been exploited in MS therapy: IFNβ treatment reduces NLRP3 activity and induces IL-10, thus decreasing the production of pro-IL-1α, pro-IL-1β and mature cytokines (121). This evidence concerns the gene IL1B and myeloid sarcoma.